Double Blind, Randomized, Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Dronedarone (SR33589B) at 300, 400, or 600 mg BID for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation.

Trial Profile

Double Blind, Randomized, Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Dronedarone (SR33589B) at 300, 400, or 600 mg BID for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2013

At a glance

  • Drugs Dronedarone (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jul 2012 Actual end date changed from May 2011 to Apr 2011 as reported by ClinicalTrials.gov.
    • 03 Aug 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top